Why Pfizer's 2017 Was Mediocre at Best Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pfizer’s 2017 wasn’t horrible. Just ho-hum. Source: BioSpace You Might Also Like Auris Abandons Hearing-Loss Drug After Phase III Flop, Stock Sinks November 27, 2017 It's Confirmed: Celgene's Former CEO and Chairman is Making a Run for the Senate February 12, 2018 AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017
AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017
